Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Voyager Therapeutics (VYGR) Operating Expenses: 2014-2024

Historic Operating Expenses for Voyager Therapeutics (VYGR) over the last 11 years, with Dec 2024 value amounting to $163.3 million.

  • Voyager Therapeutics' Operating Expenses rose 14.45% to $44.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $171.5 million, marking a year-over-year increase of 10.87%. This contributed to the annual value of $163.3 million for FY2024, which is 27.57% up from last year.
  • Per Voyager Therapeutics' latest filing, its Operating Expenses stood at $163.3 million for FY2024, which was up 27.57% from $128.0 million recorded in FY2023.
  • Voyager Therapeutics' Operating Expenses' 5-year high stood at $163.3 million during FY2024, with a 5-year trough of $91.7 million in FY2022.
  • In the last 3 years, Voyager Therapeutics' Operating Expenses had a median value of $128.0 million in 2023 and averaged $127.7 million.
  • In the last 5 years, Voyager Therapeutics' Operating Expenses dropped by 22.76% in 2021 and then skyrocketed by 39.51% in 2023.
  • Yearly analysis of 5 years shows Voyager Therapeutics' Operating Expenses stood at $143.7 million in 2020, then fell by 22.76% to $111.0 million in 2021, then declined by 17.37% to $91.7 million in 2022, then soared by 39.51% to $128.0 million in 2023, then grew by 27.57% to $163.3 million in 2024.